Archive for October, 2003

Enigmatic ImClone

Enigmatic ImClone Rarely has a company reeling from corporate malfeasance been on the receiving end of so much good news. But such is the case with ImClone Systems, as investors struggle for clues on the long-term direction of this enigma.


Click here for reuse options!
Copyright 2003 Biotechblog

IPO market abuzz with biotech offerings

IPO market abuzz with biotech offerings The buzz is biotech — at least as far as initial public offerings are concerned in the fourth quarter.


Click here for reuse options!
Copyright 2003 Biotechblog

IPO Market Abuzz with Biotech Offerings

IPO Market Abuzz with Biotech Offerings “We can expect to see the first IPO take flight in mid-October and we are sticking with our prediction … of at least a dozen IPOs getting done before the end of the year.”


Click here for reuse options!
Copyright 2003 Biotechblog

GE's Genomic Future

GE’s Genomic Future On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the more far-reaching consequences of the deal puts GE on the cutting edge of how new knowledge about genetics is used to treat patients. The deal could put General Electric in direct competition with diagnostic and […]


Click here for reuse options!
Copyright 2003 Biotechblog

GE’s Genomic Future

GE’s Genomic Future On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the more far-reaching consequences of the deal puts GE on the cutting edge of how new knowledge about genetics is used to treat patients. The deal could put General Electric in direct competition with diagnostic and […]


Click here for reuse options!
Copyright 2003 Biotechblog

Medicine's Big Bottleneck

Medicine’s Big Bottleneck If health care companies and the U.S. government do not tread carefully, concerns about the cost of developing and providing treatments could derail medical innovation. That was the consensus among top industry and regulatory figures yesterday during speeches and interviews at the Medical Innovations Summit at the Cleveland Clinic.


Click here for reuse options!
Copyright 2003 Biotechblog

Medicine’s Big Bottleneck

Medicine’s Big Bottleneck If health care companies and the U.S. government do not tread carefully, concerns about the cost of developing and providing treatments could derail medical innovation. That was the consensus among top industry and regulatory figures yesterday during speeches and interviews at the Medical Innovations Summit at the Cleveland Clinic.


Click here for reuse options!
Copyright 2003 Biotechblog

Stem cell bill eyed as lure to biotech firms

Stem cell bill eyed as lure to biotech firms A redraft may be in its future, but supporters of a proposed Bay State bill filed last winter that would formally welcome and set boundaries for stem cell research here say the measure will be an important part of the legislative agenda in the coming months.


Click here for reuse options!
Copyright 2003 Biotechblog

What's Really Banging Up Biovail?

What’s Really Banging Up Biovail? The Canadian drugmaker says a truck accident caused it to lower guidance. Wall Street skeptics think something more may be going on


Click here for reuse options!
Copyright 2003 Biotechblog

%d bloggers like this: